Differences of core genes in liver fibrosis and hepatocellular carcinoma: Evidence from integrated bioinformatics and immunohistochemical analysis

Table 4 Clinical and histologic data for healthy controls, chronic hepatitis B and hepatocellular carcinoma patients

	Control (n = 5)	CHB-S0 (n = 4)	CHB-S1-2 (n = 13)	CHB-S3-4 (n = 11)	HCC (n = 12)
Sex (M/F), n	3/2	2/2	6/7	8/3	11/1
Age, yr, mean ± SD	41.8 ± 9.5	33.0 ± 10.3	38.2 ± 8.1	40.3 ± 6.1	52.8 ± 10.5
HBeAg(+), n	0	2	9	7	3
HBV DNA, logIU/mL, median with IQR	-	5.5 (2.4, 8.5)	5.0 (2.5, 7.0)	4.7 (2.0, 6.6)	0 (0, 3.0)
ALT, U/L, median with IQR	19.2 (16.8, 28.7)	56.6 (45.0, 75.8)	39.3 (17.9, 66.3)	51.3 (29.6, 70.0)	54.7 (24.1, 105.8)
AST, U/L, median with IQR	20.7 (19.4, 22.5)	36.3 (27.2, 44.6)	27.3 (20.9, 39.9)	31.8 (23.8, 49.7)	54.8 (27.9, 111.6)
TBil, μmol/L, mean ± SD	18.9 ± 14.1	14.0 ± 4.3	12.8 ± 4.9	12.9 ± 4.8	16.8 ± 14.6
ALB, g/L, mean ± SD	45.9 ± 4.8	47.8 ± 4.3	46.5 ± 3.9	44.4 ± 5.0	41.3 ± 5.3
CHE, IU/L, mean ± SD	6191.3 ± 1908.0	11514.5 ± 3416.1	8887.5 ± 1964.8	7708.5 ± 2064.4	6538.7 ± 7065.7
AFP, ng/ml, mean ± SD or median with IQR	2.5 ± 1.4	2.0 ± 0.8	4.7 ± 6.1	11.3 ± 22.1	37.9 (9.3, 388.9)

F: Female; M: Male; ALT: Alanine transaminase; AST: Aspartate transaminase; TBil: Total bilirubin; ALB: Albumin; CHE: Cholinesterase; AFP: Alpha-fetoprotein; IQR: Interquartile range; HCC: Hepatocellular carcinoma; CHB: Chronic hepatitis B.